Mallinckrodt PLC (MNKKQ)
| Market Cap | 16.23M |
| Revenue (ttm) | 2.49B |
| Net Income (ttm) | -211.00M |
| Shares Out | 84.72M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | 0.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,042 |
| Open | 0.1980 |
| Previous Close | 0.2000 |
| Day's Range | 0.1907 - 0.1980 |
| 52-Week Range | 0.0652 - 1.1100 |
| Beta | 3.41 |
| Analysts | n/a |
| Price Target | 1.50 (+657.6%) |
| Est. Earnings Date | Nov 2, 2021 |
About MNKKQ
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products....
Financial Performance
In 2020, Mallinckrodt's revenue was $2.21 billion, a decrease of -30.01% compared to the previous year's $3.16 billion. Losses were -$944.60 million, -5.21% less than in 2019.
Financial StatementsNews
Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of U...
DUBLIN, Sept. 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached an agreement with the Official Committee of Opioid Related C...
Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns
DUBLIN, July 7, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced publication of results from the pivotal Phase 3 STRATA2016 clinical trial of S...
Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Soci...
DUBLIN, July 1, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced new treatment guidelines for sarcoidosis from the European Respiratory Society...
Mallinckrodt Wins FDA Approval For Its Regenerative Skin Burn Graft
Following four months of regulatory delays amid the COVID-19 pandemic, the FDA has finally approved Mallinckrodt Plc's (OTC: MNKKQ) regenerative tissue graft for the treatment of second-degree burns. Th...
Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in...
DUBLIN, June 15, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (...
Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Ke...
DUBLIN, May 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced data from its Phase 4, multi-center, open-label study to assess the efficacy a...
Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry ...
DUBLIN, April 30, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that data from its Phase 4 observational registry comparing the safety and e...
Silence Therapeutics receives further US$2mln under Mallinckrodt deal
Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said had received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties. In 2019, ...
National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards
ST. LOUIS, March 29, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that its Specialty Generics division has been recognized as Manufacturin...
Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of...
DUBLIN, March 10, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it has reached agreement with an ad hoc group of first lien term lenders h...
Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terli...
DUBLIN, March 4, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced publication of results from its pivotal Phase 3 CONFIRM study to assess the efficacy and safet...
Silence Therapeutics receives US$2mln as Mallinckrodt collaboration moves onto third drug target
Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it will receive US$2mln following the start of work on a third drug target as part of its research collaboration with Mallinckrodt. The two are focuse...
Here Are The Stocks With The Highest Short Interest Rate
Short interest rates can be used to predict the potential direction of an individual stock. When stocks have a high short interest rate that's a good indicator that investors believe their share prices ...
What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?
Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.
Mallinckrodt Provides Regulatory Update on StrataGraft®
DUBLIN, Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring...
Mallinckrodt (MNKKQ) Stock Sinks As Market Gains: What You Should Know
Mallinckrodt (MNKKQ) closed the most recent trading day at $0.50, moving -1.76% from the previous trading session.
Mallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
DUBLIN, Jan. 29, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced that it received a score of 100 on the Human Rights Campaign Foundation's 2021 Corporate Equal...
The Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begi...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...
Mallinckrodt (MNKKQ) Gains As Market Dips: What You Should Know
Mallinckrodt (MNKKQ) closed the most recent trading day at $0.23, moving +1.7% from the previous trading session.
The Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Sharehold...
NEW YORK, Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending...
Top Ranked Value Stocks to Buy for December 21st
Top Ranked Value Stocks to Buy for December 21st
Top Ranked Value Stocks to Buy for December 17th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 17th
Mallinckrodt Announces Real World Data on Hepatorenal Syndrome (HRS) and Acute Kidney Injury (AKI) in Patients with L...
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patients hospit...
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrom...
DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced results from a post hoc analysis of a retrospective chart review study of terlipressin in pati...
Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 E...